Alkem在印度为HER2-呈阳性的乳腺癌治疗注射可负担得起的类似Pertuza的生物注射。 Alkem launches affordable biosimilar Pertuza injection in India for HER2-positive breast cancer treatment.

Alkem实验室在印度为治疗HER2-阳性乳腺癌开展了Pertuza注射,其生物与pertuzumab相似,用于治疗HER2-阳性乳癌。 Alkem Laboratories has launched Pertuza injection, a biosimilar to pertuzumab, in India for treating HER2-positive breast cancer. 该药物是本地开发和制造的,目的是改善这种常见癌症的妇女获得负担得起的治疗的机会。 Developed and manufactured indigenously, the drug aims to improve access to affordable treatment for women with this common cancer type. 临床试验表明,它在功效、安全和免疫力方面与参考产品相匹配。 Clinical trials showed it matches the reference product in efficacy, safety, and immunogenicity. 该发射支持Alkem更广泛的肿瘤组合及其通过科学创新和国内生产扩大获得关键癌症治疗机会的使命。 The launch supports Alkem’s broader oncology portfolio and its mission to expand access to critical cancer therapies through scientific innovation and domestic production.